Application of the drug Enroflon® gel for the treatment of cows with subclinical mastitis

Abstract

 Relevance. Inflammation of the mammary gland — mastitis — in cows is widespread. Of particular danger is subclinical mastitis, which proceeds latently, without visible clinical signs. During one, two or more lactations, subclinical mastitis leads the affected quarter to agalactia and atrophy. Animals that had subclinical mastitis lose milk productivity by an average of 10–15%; along with a decrease in milk secretion in animals with subclinical mastitis, its qualitative characteristics also change.

Materials and methods. The work was carried out in the livestock economy of Dagestan Republic on black-and-white Holsteinized cows aged from three to six years, suffering from subclinical mastitis, in the amount of 42 heads, divided into two groups (experiment and control). The cows of the experimental group (n = 25) were injected intracisternally with Enroflon® gel in dose of 7.5 ml (syringe-dispenser) twice a day for 3–4 days. Control animal (n = 17) were injected into the affected quarter of the udder with Mastisan A in dose of 10 ml once a day until recovery. The diagnosis of the disease was established in accordance with the “Manual on the diagnosis, therapy and prevention of mastitis in cows” (M., 2000). Blood and udder secretions were taken from 5 cows of each group before the administration of the drugs and on the 5th day after the end of treatment for laboratory research. The suprauterine lymph nodes were examined by palpation.

Research results. As a result of production tests, Enroflon® gel showed a high therapeutic efficiency (96,0%), hematological and biochemical parameters of blood and physicochemical — of milk recovered completely on the fifth day after treatment.